Boston Scientific Corporation (BSX) Revenue by Segment

Boston Scientific revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended June 30, 2026), Boston Scientific's largest business segment was Cardiovascular, with $3.62 billion or 67% of revenue, up 8.3% from a year earlier. Next: MedSurg (33%).

By product or service, Interventional Cardiology Therapies brought in 24%, Electrophysiology (EP) brought in 17% and Global Endoscopy (Endo) Reporting Unit brought in 15% of revenue in Q2 fiscal 2026.

By region, United States brought in 63% and Non-US brought in 37% of revenue in Q2 fiscal 2026.

The fastest-growing business segment from a year earlier was Cardiovascular (+8.3%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

Boston Scientific Corporation

BSXHealthcare

United States

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

CardiovascularMedSurgRhythm and NeuroBsxSpecialty Pharmaceuticals

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before	Trend
Cardiovascular	USD 3.62B	66.6%	+8.3%
MedSurg	USD 1.82B	33.4%	+5.9%

Sum of items USD 5.44B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
Cardiovascular	3.6B	3.5B	3.5B	3.3B	3.3B	3.1B	–	2.7B	2.6B	2.4B	–	2.2B	2.2B	2.1B	–	2.0B	2.0B	1.9B	1.9B	1.8B	1.9B	1.7B	1.0B	–	834.0M	1.0B	–	1.1B	1.0B	972.0M	971.0M	908.0M	965.0M	933.0M	–	857.0M
MedSurg	1.8B	1.7B	1.8B	1.7B	1.7B	1.6B	–	1.5B	1.5B	1.4B	–	1.3B	1.4B	1.3B	–	1.2B	1.2B	1.2B	1.2B	1.1B	1.2B	1.1B	891.0M	–	576.0M	774.0M	–	845.0M	818.0M	766.0M	800.0M	746.0M	751.0M	711.0M	–	676.0M
Rhythm and Neuro	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	767.0M	–	525.0M	703.0M	–	780.0M	786.0M	757.0M	789.0M	740.0M	775.0M	736.0M	–	689.0M
Bsx	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.6B	–	–	–	–	–	–	–	–	–	–	–	–
Specialty Pharmaceuticals	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	23.0M	–	–	–	–	–	–	–	–

Boston Scientific revenue by business segment, last 4 quarters

Business segment	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Cardiovascular	$3.6B	$3.5B	$3.3B	$3.3B	67%
MedSurg	$1.8B	$1.7B	$1.7B	$1.7B	33%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Boston Scientific revenue by product or service, last 4 quarters

Product or service	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Interventional Cardiology Therapies	$1.3B	$1.2B	$686.0M	$1.2B	24%
Electrophysiology (EP)	$916.0M	$905.0M	$865.0M	$840.0M	17%
Global Endoscopy (Endo) Reporting Unit	$793.0M	$736.0M	$747.0M	$737.0M	15%
Global Urology and Pelvic Health Reporting Unit	$684.0M	$646.0M	$682.0M	$676.0M	13%
Cardiac Rhythm Management	$585.0M	$578.0M	$578.0M	$590.0M	11%
Watchman	$507.0M	$506.0M	$512.0M	$486.0M	9%
Global Neuromodulation (NM) Reporting Unit	$341.0M	$318.0M	$293.0M	$303.0M	6%
Interventional Oncology and Embolization	$283.0M	$268.0M	–	$251.0M	5%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Boston Scientific revenue by region, last 4 quarters

Region	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
United States	$3.4B	$3.3B	$3.3B	$3.2B	63%
Non-US	$2.0B	$1.9B	$1.8B	$1.8B	37%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

What are Boston Scientific's business segments?

Cardiovascular and MedSurg (as reported for Q2 fiscal 2026).

Which business segment makes the most money for Boston Scientific?

Cardiovascular: $3.62 billion, or 67% of revenue, in Q2 fiscal 2026.

What are Boston Scientific's main products and services?

By revenue in Q2 fiscal 2026: Interventional Cardiology Therapies (24%), Electrophysiology (EP) (17%), Global Endoscopy (Endo) Reporting Unit (15%) and Global Urology and Pelvic Health Reporting Unit (13%).

Where does Boston Scientific make its money?

By region in Q2 fiscal 2026: United States (63%) and Non-US (37%).

MoreBoston Scientific stock overview Boston Scientific financials Boston Scientific executive team Boston Scientific shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

CardiovascularMedSurgRhythm and NeuroBsxSpecialty Pharmaceuticals

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before	Trend
Cardiovascular	USD 3.62B	66.6%	+8.3%
MedSurg	USD 1.82B	33.4%	+5.9%

Sum of items USD 5.44B. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
Cardiovascular	3.6B	3.5B	3.5B	3.3B	3.3B	3.1B	–	2.7B	2.6B	2.4B	–	2.2B	2.2B	2.1B	–	2.0B	2.0B	1.9B	1.9B	1.8B	1.9B	1.7B	1.0B	–	834.0M	1.0B	–	1.1B	1.0B	972.0M	971.0M	908.0M	965.0M	933.0M	–	857.0M
MedSurg	1.8B	1.7B	1.8B	1.7B	1.7B	1.6B	–	1.5B	1.5B	1.4B	–	1.3B	1.4B	1.3B	–	1.2B	1.2B	1.2B	1.2B	1.1B	1.2B	1.1B	891.0M	–	576.0M	774.0M	–	845.0M	818.0M	766.0M	800.0M	746.0M	751.0M	711.0M	–	676.0M
Rhythm and Neuro	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	767.0M	–	525.0M	703.0M	–	780.0M	786.0M	757.0M	789.0M	740.0M	775.0M	736.0M	–	689.0M
Bsx	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.6B	–	–	–	–	–	–	–	–	–	–	–	–
Specialty Pharmaceuticals	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	23.0M	–	–	–	–	–	–	–	–